Citations

Clear

219 citation(s) found for "Do, Ron".

Analysis of Left Ventricular Indexes and Mortality Among Asian Adults With Hemodynamically Significant Chronic Aortic Regurgitation
Lee, Chien‐Chang , Su, Chin‐Hua , Kitano, Tetsuji , Tsai, Chieh-Mei , Nishimura, Kunihiro , Lo, Hao-Yun, Hsu, Ron‐Bin , Chen, Yih‐Sharng , Chen, Wen‐Jone , Mankad, Rekha , Chen, Yih-Sharng , Yang, Li‐Tan , Amano, Masashi , Nabeshima, Yosuke , Hung, Chung‐Lieh , Nakaoku, Yuriko , Ogata, Soshiro , Lo, Hao-Yun, Pellikka, Patricia A. , Ho, Yi‐Lwun , Takeuchi, Masaaki , Izumi, Chisato

Mayo Clinic

JAMA Network Open | March 24, 2023 | Volume: 6 | Issue: 3 | Pages: e234632

10.1001/jamanetworkopen.2023.4632 | PMID 36961461 Get It

ImportanceChronic hemodynamically significant aortic regurgitation (AR) is associated with excess risk of death, yet data for Asian patients are lacking, and whether Asian patients can abide by Western guidelines as to when aortic valve surgery should be performed is unknown.ObjectiveTo assess AR presentation and cutoffs of left ventricular ejection fraction (LVEF), LV end-systolic dimension index (LVESDi), and LV end-systolic volume index (LVESVi) that are associated with risk of death in Asian patients with AR.Design, Setting, and ParticipantsThis retrospective cohort study included consecutive patients with chronic, moderately severe to severe AR from 3 tertiary referral centers (2 in Japan and 1 in Taiwan) from June 11, 2008, through November 19, 2020, with follow-up through November 11, 2021.ExposuresAortic regurgitation severity, graded by a comprehensive integrated approach.Main Outcomes and MeasuresThe primary outcome was the association between volume-derived LVEF, LVESDi, and LVESVi and all-cause death (ACD). The secondary outcome was the association of these LV indexes with cardiovascular death (CVD). Clinical and echocardiographic data were analyzed retrospectively. A de novo disk-summation method was used to derive LV volumes and volume-derived LVEF.ResultsOf 1259 patients (mean [SD] age, 64 [17] years; 934 [74%] male), 515 (41%) were Japanese and 744 (59%) were Taiwanese. The median follow-up was 4.1 years (IQR, 1.56-7.24 years). The mean (SD) body surface area was 1.67 (0.21) m2; LVEF, 55% (11%); LVESDi, 24.7 (5.7) mm/m2; LVESVi, 50.1 (28.0) mL/m2; and indexed mid–ascending aorta size, 24.7 (5.5) mm/m2. Aortic valve surgery occurred in 483 patients (38%); 240 patients (19%) died during follow-up. Overall mean (SD) 8-year survival was 74% (2%). Separate multivariate models adjusted for covariates demonstrated independent associations of LVEF, LVESDi, and LVESVi with ACD (LVEF: hazard ratio [HR] per 10%, 0.80; 95% CI, 0.70-0.92; P = .002; LVESDi: HR, 1.04; 95% CI, 1.01-1.06; P = .002; LVESVi: HR per 10 mL/m2, 1.11; 95% CI, 1.05-1.17; P < .001) and CVD (LVEF: HR per 10%, 0.69; 95% CI, 0.56-0.85; P < .001; LVESDi: HR, 1.05; 95% CI, 1.01-1.09; P = .01; LVESVi per 10 mL/m2: HR, 1.15; 95% CI, 1.06-1.24; P < .001). In the total cohort, spline curves showed that mortality started to increase for an LVEF of 53% or less, LVESDi of 22 mm/m2 or greater, and LVESVi of 46 mL/m2 or greater for both ACD and CVD. Early surgery was beneficial in 3 strata of LVESDi (<20, 20 to <25, and ≥25 mm/m2) and 2 strata of LVESVi (<46 and ≥46 mL/m2).Conclusions and RelevanceThis multicenter cohort study of Asian patients with hemodynamically significant AR found cutoff values of LVEF, LVESDi, and LVESVi that were associated with increased risk of death. These findings suggest that Western guidelines seem applicable in Asian patients and, most importantly, that indexed LV parameters with a lower cutoff could be used in discriminating patients with excess mortality risk.
Characteristics and outcomes of patients with gastroparesis using enteral and/or exclusive parenteral nutrition
Parkman, Henry P. , Murray, Helen Burton , Yates, Katherine P. , Grover, Madhusudan , Malik, Zubair , Schey, Ron , Bulat, Robert, Koch, Kenneth L. , Sarosiek, Irene , Shulman, Robert J. , Farrugia, Gianrico , Miriel, Laura , Tonascia, James , Hamilton, Frank A., Pasricha, Pankaj J. , McCallum, Richard W. , Abell, T L , Parkman, H P , Burton-Murray, Helen , Blackford, Amanda , Kuo, Braden , Chumpitazi, Bruno P. , Abell, Thomas L.

Mayo Clinic

Journal of Parenteral and Enteral Nutrition | March 4, 2023 | Volume: 47 | Issue: 4 | Pages: 541-549

10.1002/jpen.2493 | PMID 36871132 Get It

AbstractBackgroundPatients with gastroparesis (Gp) may need enteral nutrition (EN) or exclusive parenteral nutrition (PN). Among patients with Gp, we aimed to (1) identify the frequency of EN and exclusive PN use and (2) explore characteristics of patients using EN and/or exclusive PN compared with those using oral nutrition (ON), including changes over 48 weeks.MethodsPatients with Gp underwent history and physical examination, gastric emptying scintigraphy, water load satiety testing (WLST), and questionnaires assessing gastrointestinal symptoms and quality of life (QOL). Patients were observed 48 weeks.ResultsOf 971 patients with Gp (idiopathic, 579; diabetic, 336; post–Nissen fundoplication, 51), 939 (96.7%) were using ON only, 14 (1.4%) using exclusive PN, and 18 (1.9%) using EN. Compared with patients receiving ON, patients receiving exclusive PN and/or EN were younger, had lower body mass index, and had greater symptom severity. Patients receiving exclusive PN and/or EN had lower physical QOL but not mental QOL or Gp‐related QOL scores. Patients receiving exclusive PN and/or EN ingested less water during WLST but did not have worse gastric emptying. Of those who had been receiving exclusive PN and/or EN, 50% and 25%, respectively, resumed ON at 48‐week follow‐up.ConclusionsThis study describes patients with Gp requiring exclusive PN and/or EN for nutrition support, who represent a small (3.3%) but important subset of patients with Gp. Unique clinical and physiological parameters are associated with this subset and provide insight into the use of nutrition support in Gp.
Abstract PD18-01: Adjuvant Trastuzumab Emtansine Versus Paclitaxel plus Trastuzumab for Stage I HER2+ Breast Cancer: 5-year results and correlative analyses from ATEMPT (TBCRC033)
Tayob, Nabihah , Dang, Chau T. , Isakoff, Steven J. , Valero, Vicente , Faggen, Meredith, Mulvey, Therese M. , Bose, Ron , Weckstein, Douglas, Reeder‐Hayes, Katherine E. , Rugo, Hope, Ramaswamy, Bhuvaneswari , Zuckerman, Dan Sayam , Hart, Lowell L., Gadi, Vijayakrishna K. , Constantine, Michael, Cheng, Kit , Garrett, Audrey Merrill, Albain, Kathy S. , DeFusco, Patricia, Tung, Nadine, Ardman, Blair, Nanda, Rita , Jankowitz, Rachel C. , Rimawi, Mothaffar F. , Pohlmann, Paula R. , Poznak, Catherine Van , Forero-Torres, Andres , Liu, Minetta C. , Ruddy, Kathryn, Waks, Adrienne G. , DeMeo, Michelle K. , Burstein, Harold J. , Partridge, Ann, Viale, Giuseppe , Hui, Winnie W. , Schneider, Bryan P. , Krop, Ian E. , Tolaney, Sara M. , Rimawi, Mothaffar , Pohlmann, Paula , Tarantino, Paolo , Yardley, Denise Aysel , Wolff, Antonio C. , Marcom, Paul Kelly , Tung, Nadine , Abramson, Vandana G. , Ruddy, Kathryn J. , Zheng, Yue , Barroso‐Sousa, Romualdo , DiLullo, Molly K. , Curigliano, Giuseppe , Winer, Eric P. , Mittendorf, EA , Prat, Aleix

Mayo Clinic

Cancer Research | March 2, 2023 | Volume: 83 | Issue: 5_Supplement | Pages: PD18-01-PD18-01

10.1158/1538-7445.sabcs22-pd18-01 Get It

Abstract Background: The ATEMPT trial primary analysis found that one year of adjuvant trastuzumab emtansine (T-DM1) achieved a 3-year iDFS of 97.8% for patients with stage I HER2+ breast cancer, but was not associated with fewer clinically relevant toxicities (CRTs) compared with paclitaxel and trastuzumab (TH). In this end-of-study analysis, we report 5-year survival outcomes and correlative analyses from the trial. Methods: Patients with stage I centrally confirmed HER2+ breast cancer were randomly assigned 3:1 to adjuvant T-DM1 for one year or TH and received T-DM1 3.6 mg/kg IV every 3 weeks for 17 cycles or paclitaxel 80 mg/m2 IV with weekly trastuzumab IV followed by trastuzumab for 9 months. The co-primary objectives were to compare the incidence of CRTs between the 2 arms and to evaluate iDFS in patients receiving T-DM1. To investigate proteomic correlates of recurrence, spatial proteomic analyses were performed on samples from 13 patients experiencing iDFS events (cases) and 24 matched controls using the NanoString GeoMx Digital Spatial Profiler. The impact of HER2 heterogeneity on outcomes was investigated among 17 cases and 51 matched controls by fluorescence in-situ hybridization (FISH). HER2 genetic heterogeneity was assessed by scrutinizing the whole tumor area and defined as the occurrence of HER2 gene amplification in >5% but < 50% invasive tumor cells. The risk of recurrence was evaluated centrally with the HER2DX genomic assay from 225 primary tumor samples. Germline whole genome sequencing (WGS) was conducted among 55 patients experiencing T-DM1-induced thrombocytopenia and/or bleeding and 55 matched controls to identify genomic correlates for this side effect. Results: A total of 497 patients who initiated protocol therapy were included in this analysis (383 T-DM1 and 114 TH). After a median follow up 5.8 years, among patients receiving T-DM1 there were a total of 11 iDFS events, with 3 distant recurrences. The 5-year iDFS for T-DM1 was 97.0% (95% CI, 95.3-98.8%), the 5-year recurrence-free interval (RFI) was 98.6% (95% CI: 97.4-99.8%) and the 5-year overall survival (OS) for T-DM1 was 97.8 % (95% CI, 96.3-99.3%). Although the study was not powered to evaluate the efficacy of TH, among the 114 patients receiving TH, a total of 9 iDFS events were observed, including 2 distant events; the 5-year iDFS with TH was 91.3% (95% CI: 86.0-96.9%), 5-year RFI was 93.3% (95% CI: 88.6-98.2%) and 5-year OS was 97.9% (95% CI: 95.2-100%). A total of 56 samples were evaluable for heterogeneity analyses, among which 14% (n=8) harbored HER2 genetic heterogeneity. Spatial proteomic analyses found that NF1 (adjusted p=0.72 × 10-6) and CTLA-4 (adjusted p=0.15 × 10-3) were significantly upregulated in primary samples from cases, while cleaved caspase 9, CD25, GITR, ICOS, p53 and PD-L2 were significantly upregulated in controls (all with adjusted p< 0.05). Germline WGS found that the top gene associations with thrombocytopenia and thrombocytopenia or bleeding were ALMS1 (p=0,19 × 10-3) and APBA3 (p=0,23 × 10-3), respectively, although none reaching the threshold for genome wide significance. rs62143195 and rs114169776 were the top single nucleotide polymorphisms associated with thrombocytopenia and thrombocytopenia or bleeding, respectively. Data on the impact of HER2 heterogeneity and of HER2DX score on survival outcomes will be presented. Conclusion: With longer follow-up, adjuvant T-DM1 confirmed outstanding long-term outcomes among patients with stage I HER2+ breast cancer, demonstrating a 5-year RFI of 98.6%. Spatial proteomic analyses identified a potential association between NF1 and CTLA-4 expression with recurrence. Details on the impact of HER2 heterogeneity and HER2DX assay on prognosis will be presented. Citation Format: Paolo Tarantino, Nabihah Tayob, Chau T Dang, Denise Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Douglas Weckstein, Antonio C. Wolff, Katherine Reeder-Hayes, Hope Rugo, Bhuvaneswari Ramaswamy, Dan Zuckerman, Lowell Hart, Vijayakrishna K. Gadi, Michael Constantine, Kit Cheng, Audrey Merrill Garrett, Paul K. Marcom, Kathy S. Albain, Patricia DeFusco, Nadine Tung, Blair Ardman, Rita Nanda, Rachel C. Jankowitz, Mothaffar Rimawi, Vandana Abramson, Paula R. Pohlmann, Catherine Van Poznak, Andres Forero-Torres, Minetta C. Liu, Kathryn Ruddy, Yue Zheng, Romualdo Barroso-Sousa, Adrienne Waks, Michelle K. DeMeo, Molly K. DiLullo, Giuseppe Curigliano, Harold Burstein, Ann Partridge, Eric Winer, Giuseppe Viale, Winnie Hui, Elizabeth A. Mittendorf, Bryan P. Schneider, Aleix Prat, Ian Krop, Sara Tolaney. Adjuvant Trastuzumab Emtansine Versus Paclitaxel plus Trastuzumab for Stage I HER2+ Breast Cancer: 5-year results and correlative analyses from ATEMPT (TBCRC033) [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr PD18-01.
Proton Magnetic Resonance Spectroscopy at Term Age is Not Predictive of Neurodevelopmental Outcome in Very Low Birth Weight Preterm Infants
Brussel, E.M. Van, Barnes, Pat, Sutcliffe, Trenna L., Dermon, J. D., Ariagno, Ron, Brussel, E. M. Van, Mirmiran, Majid , Spielman, Daniel M.

Mayo Clinic

Journal of Investigative Medicine | January 6, 2023 | Volume: 54 | Issue: 1_suppl | Pages: 128-128

10.1177/108155890605401s162 Get It

RELATIONSHIPS OF CEREBRAL PERFUSION WITH GAIT SPEED ACROSS AGE AND SYSTOLIC BLOOD PRESSURE LEVELS
Windham, B. Gwen , Griswold, Michael , Petersen, Ron, Sullivan, Kevin , Mosley, Thomas H. , Mielke, Michelle M. , Knopman, David S. , Vemuri, Prashanthi

Mayo Clinic

Innovation in Aging | December 20, 2022 | Volume: 6 | Issue: Supplement_1 | Pages: 710-710

10.1093/geroni/igac059.2596 Get It

Abstract We hypothesized that poorer cerebral perfusion could impair mobility, particularly at lower systolic blood pressure (SBP). Cerebral perfusion was measured via arterial spin-labelled (ASL)-MRI in community-dwelling adults of the Mayo Clinic Study of Aging. Usual-pace gait speed was assessed over 5.6 meters on an electronic mat. Linear regression models estimated cross-sectional gait speed associations with ASL and modifying effects of age and SBP, adjusting for sex and body mass index. Results report differences in gait speed (meter/second) per standard deviation (SD) lower ASL or SBP (mean=139.1 mmHg, SD=19.7 mmHg). Among 479 participants (aged 31-94 years; mean age 67.6 years; 44% women; mean gait speed 1.17m/s), relationships of ASL with gait speed varied by age and SBP (ASL-x-age interaction: p<.007; ASL-x-SBP interaction: p<.007). At age 65, 75 or 85 years and a SBP of 120mmHg, each SD lower ASL was associated with a 0.04 m/s (0.01,0.07), 0.07 m/s (0.04,0.10), and 0.09 m/s (0.05,0.13) slower gait speed at respective ages. At age 65, 75 or 85 years with low ASL (1 SD below the mean), each SD lower SBP was associated with 0.06 (0.02,0.09) m/s, 0.03 (0.01,0.06) m/s or .01 (-0.02,0.04) m/s slower gait speed, respectively. With high ASL (mean ASL+1SD), lower SBP trended towards faster gait at older age, e.g. estimated gait speed was 0.04 m/s (0.00,0.09) faster for each SD lower SBP at age 85years. Poorer cerebral perfusion may contribute to slower gait, particularly with lower SBP. The interrelations of cerebral perfusion, SBP, and age with mobility merit further study.
Cross-Ancestry Investigation of Venous Thromboembolism Genomic Predictors
Thibord, Florian , Klarin, Derek , Brody, Jennifer A. , Chen, Ming‐Huei , Levin, Michael G. , Chasman, Daniel I. , Goode, Ellen L. , Teder‐Laving, Maris , Martínez-Pérez, Ángel , Daian-Bacq, Delphine, Ito, Kaoru , Natarajan, Pradeep , Lutsey, Pamela L. , Nadkarni, Girish N. , Vries, Paul S. de , Wolford, Brooke N. , Pattee, Jack , Brækkan, Sigrid K. , Li‐Gao, Ruifang , Saut, Noémie , Sept, Corriene, Judy, Renae , O’Donnell, Christopher J. , Giulianini, Franco, Boland, Anne , Empana, Jean‐Philippe , Gilliland, Thomas , Do, Ron , Wang, Xin , Zhou, Wei , Soria, José Manuel , Souto, Juan Carlos , Haessler, Jeffery, Hindberg, Kristian , Bartz, Traci M. , Heckbert, Susan R. , Armasu, Sebastian M. , Brumpton, Ben , Smadja, David M. , Jouven, Xavier , Loos, Ruth J. F. , Sabater‐Lleal, Maria , Pankow, James S. , Reiner, Alex P. , Vlieg, Astrid van Hylckama , Deleuze, Jean-François, Skogholt, Anne Heidi , Emmerich, Joseph , Tang, Weihong , Jackson, Rebecca D. , Hansen, John‐Bjarne , Morange, Pierre‐Emmanuel , Kabrhel, Christopher , Johnson, Andrew D. , Smith, Nicholas L. , Martinez-Perez, Angel , Aïssi, Dylan , Ito, Kaoru , Natarajan, Pradeep , Lutsey, Pamela L , Nadkarni, Girish N , de Vries, Paul S , Wolford, Brooke N , Kooperberg, Charles , Braekkan, Sigrid K , Li-Gao, Ruifang , Saut, Noemie , Germain, Marine , Wiggins, Kerri L , Ko, Darae , O'Donnell, Christopher J , Taylor, Kent D , de Andrade, Mariza , Nøst, Therese H , Boland, Anne , Empana, Jean Philippe , Gilliland, Thomas , Do, Ron , Wang, Xin , Manuel Soria, Jose , Carlos Souto, Juan , Pankratz, Nathan , Rosendaal, Frits R , Turman, Constance , Olaso, Robert , Bartz, Traci M , Lynch, Julie A , Heckbert, Susan R , Brumpton, Ben , Smadja, David M , Komuro, Issei , Clapham, Katharine R , Loos, Ruth J F , Willer, Cristen J , Sabater-Lleal, Maria , Pankow, James S , Reiner, Alexander P , Ridker, Paul M. , Rader, Daniel J , Min Lee, Kyung , Psaty, Bruce M , Rich, Stephen S , Vy, Ha My T , Tang, Weihong , Damrauer, Scott M , Johnson, Andrew D , Smith, Nicholas L , Chasman, Daniel I , Brody, Jennifer A , Hveem, Kristian , Cuéllar-Partida, Gabriel , Kooperberg, Charles , Germain, Marine , Wiggins, Kerri L. , Taylor, Kent D. , Andrade, Mariza de , Koyama, Satoshi , Huffman, Jennifer E. , Pankratz, Nathan , Turman, Constance , Kember, Rachel L. , Lynch, Julie A. , Morelli, Vânia Maris , Deleuze, Jean‐François , Kraft, Peter , Lee, Kyung Min , Psaty, Bruce M. , Suchon, Pierre , Rich, Stephen S. , Trégouët, David‐Alexandre

Mayo Clinic

Circulation | October 17, 2022 | Volume: 146 | Issue: 16 | Pages: 1225-1242

10.1161/circulationaha.122.059675 | PMID 36154123 Get It

Background: Venous thromboembolism (VTE) is a life-threatening vascular event with environmental and genetic determinants. Recent VTE genome-wide association studies (GWAS) meta-analyses involved nearly 30 000 VTE cases and identified up to 40 genetic loci associated with VTE risk, including loci not previously suspected to play a role in hemostasis. The aim of our research was to expand discovery of new genetic loci associated with VTE by using cross-ancestry genomic resources. Methods: We present new cross-ancestry meta-analyzed GWAS results involving up to 81 669 VTE cases from 30 studies, with replication of novel loci in independent populations and loci characterization through in silico genomic interrogations. Results: In our genetic discovery effort that included 55 330 participants with VTE (47 822 European, 6320 African, and 1188 Hispanic ancestry), we identified 48 novel associations, of which 34 were replicated after correction for multiple testing. In our combined discovery-replication analysis (81 669 VTE participants) and ancestry-stratified meta-analyses (European, African, and Hispanic), we identified another 44 novel associations, which are new candidate VTE-associated loci requiring replication. In total, across all GWAS meta-analyses, we identified 135 independent genomic loci significantly associated with VTE risk. A genetic risk score of the significantly associated loci in Europeans identified a 6-fold increase in risk for those in the top 1% of scores compared with those with average scores. We also identified 31 novel transcript associations in transcriptome-wide association studies and 8 novel candidate genes with protein quantitative-trait locus Mendelian randomization analyses. In silico interrogations of hemostasis and hematology traits and a large phenome-wide association analysis of the 135 GWAS loci provided insights to biological pathways contributing to VTE, with some loci contributing to VTE through well-characterized coagulation pathways and others providing new data on the role of hematology traits, particularly platelet function. Many of the replicated loci are outside of known or currently hypothesized pathways to thrombosis. Conclusions: Our cross-ancestry GWAS meta-analyses identified new loci associated with VTE. These findings highlight new pathways to thrombosis and provide novel molecules that may be useful in the development of improved antithrombosis treatments.
A nationwide analysis of cardiac sarcoidosis and related in-hospital outcomes
Victor, Varun, Patel, Harsh , Deshmukh, A D, Feitell, Scott , Blankstein, Ron , Thakkar, Samarthkumar , DeSimone, Christopher V. , Blankstein, Ron

Mayo Clinic

European Heart Journal | October 15, 2022 | Volume: 43 | Issue: Supplement_2 | Pages: No page available

10.1093/eurheartj/ehac544.2647 Get It

Abstract Introduction Sarcoidosis is a multisystem disorder characterized by an autoimmune response to an unidentified antigen in genetically susceptible persons. Despite clinically detectable cardiac manifestations of sarcoidosis occurring in approximately 5% of patients, recent studies have revealed cardiac involvement to be at 25% in patients with the disease, highlighting the fact that cardiac involvement in sarcoidosis is much more common than was once thought to be. Purpose With cardiac involvement in sarcoidosis being increasingly recognized due to the availability of advanced cardiac imaging, large scale data regarding in-hospital mortality and clinical outcomes of patients admitted with cardiac sarcoidosis (CS) is lacking. Our study aimed to fill this knowledge gap by analyzing demographics and in-hospital outcomes of a large cohort of patients admitted with CS across the United States (US). Methods We analyzed data from the national inpatient sample (NIS) database between October 2015 to December 2018 to identify patients who had been admitted with primary and secondary diagnoses of CS. The NIS is an administrative database sponsored by the Agency for Healthcare Research and Quality consisting of data from 46 participating states, representing more than 95% of the US population and providing nationwide estimates of over 35 million hospitalizations annually. The NIS uses de-identified hospital discharges as samples and hence no additional ethical committee approval was required. International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) code D86.85 was used to identify hospitalizations with CS in patients aged 18 years or older. SAS 9.4 (SAS Institute, Inc, Cary, NC) was used for statistical analyses. Results A total of 4275 patients were included in the analysis. A higher proportion of patients with CS were females (62.43% vs. 37.57%). Hypertension was the most common comorbidity (43.99%), followed by hyperlipidemia (39.21%) and chronic kidney disease (26.95%). All-cause in-hospital mortality was 2.57%. Atrial fibrillation (AF) was the most common arrhythmia (28.12%), followed by ventricular tachycardia (VT) (22.52%). About 16% of CS patients underwent implantable cardioverter-defibrillator (ICD) implantation during hospital stay. About 42% of patients had concurrent heart failure, out of whom 33.84% had heart failure with reduced ejection fraction (HFrEF). Mean length of hospital stay was 5 days (3–8 days), and the mean cost of hospitalization was $14,177 ($7,121–35,993). Conclusion Given the low prevalence of CS, most of the available studies have been retrospective in nature, based on small sample sizes. Despite being retrospective and cross-sectional, our study has the advantage of being based on a nationally representative sample population, providing key formation on the demographics and in-hospital outcomes of patients with CS. Funding Acknowledgement Type of funding sources: None.
Hepatobiliary and pancreatic resection for cholangiocarcinoma in patients with primary sclerosing cholangitis
Pery, Ron, Smoot, Rory L. , Nagorney, David M. , Smoot, Rory L , Thiels, Cornelius A. , Cleary, Sean P. , Vierkant, Robert A. , Ilyas, Sumera I. , Gores, Gregory J.

Mayo Clinic

British Journal of Surgery | October 5, 2022 | Volume: 109 | Issue: 11 | Pages: 1032-1035

10.1093/bjs/znac229 | PMID 35848775 Get It

Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT
Jayne, David , Walsh, Michael , Merkel, Peter A. , Peh, Chen Au , Szpirt, Wladimir , Puéchal, Xavier , Fujimoto, Shouichi , Hawley, Carmel M. , Khalidi, Nader , Jones, Rachel , Gregorini, Gina , Harper, Lorraine , Clark, William F. , Smyth, Lucy , Ito‐Ihara, Toshiko , Brezina, Biljana , Mazzetti, Andrea , McAlear, Carol A. , Reidlinger, Donna , Mehta, Samir , Ives, Natalie , Brettell, Elizabeth , Jarrett, Hugh , Wheatley, Keith , Broadhurst, Elizabeth , Casian, Alina , Pusey, Charles D. , Hawley, Carmel , Flossmann, Oliver , Wald, Ron , Girard, Louis , Levin, Adeera , Gregorini, Gina , Harper, Lorraine , Clark, William , Pagnoux, Christian , Specks, Ulrich , Smyth, Lucy , Ito-Ihara, Toshiko , de Zoysa, Janak , Brezina, Biljana , Mazzetti, Andrea , McAlear, Carol A , Reidlinger, Donna , Mehta, Samir , Ives, Natalie , Brettell, Elizabeth A , Jarrett, Hugh , Wheatley, Keith , Broadhurst, Elizabeth , Casian, Alina , Pusey, Charles D , Merkel, Peter A , Khalidi, Nader A , Jayne, David , Pagnoux, Christian , Specks, Ulrich

Mayo Clinic

Health Technology Assessment | September 26, 2022 | Volume: 26 | Issue: 38 | Pages: 1-60

10.3310/pnxb5040 | PMID 36155131 Get It

Background Anti-neutrophil cytoplasm antibody-associated vasculitis is a multisystem, autoimmune disease that causes organ failure and death. Physical removal of pathogenic autoantibodies by plasma exchange is recommended for severe presentations, along with high-dose glucocorticoids, but glucocorticoid toxicity contributes to morbidity and mortality. The lack of a robust evidence base to guide the use of plasma exchange and glucocorticoid dosing contributes to variation in practice and suboptimal outcomes. Objectives We aimed to determine the clinical efficacy of plasma exchange in addition to immunosuppressive therapy and glucocorticoids with respect to death and end-stage renal disease in patients with severe anti-neutrophil cytoplasm antibody-associated vasculitis. We also aimed to determine whether or not a reduced-dose glucocorticoid regimen was non-inferior to a standard-dose regimen with respect to death and end-stage renal disease. Design This was an international, multicentre, open-label, randomised controlled trial. Patients were randomised in a two-by-two factorial design to receive either adjunctive plasma exchange or no plasma exchange, and either a reduced or a standard glucocorticoid dosing regimen. All patients received immunosuppressive induction therapy with cyclophosphamide or rituximab. Setting Ninety-five hospitals in Europe, North America, Australia/New Zealand and Japan participated. Participants Participants were aged ≥ 16 years with a diagnosis of granulomatosis with polyangiitis or microscopic polyangiitis, and either proteinase 3 anti-neutrophil cytoplasm antibody or myeloperoxidase anti-neutrophil cytoplasm antibody positivity, and a glomerular filtration rate of < 50 ml/minute/1.73 m2 or diffuse alveolar haemorrhage attributable to active anti-neutrophil cytoplasm antibody-associated vasculitis. Interventions Participants received seven sessions of plasma exchange within 14 days or no plasma exchange. Oral glucocorticoids commenced with prednisolone 1 mg/kg/day and were reduced over different lengths of time to 5 mg/kg/day, such that cumulative oral glucocorticoid exposure in the first 6 months was 50% lower in patients allocated to the reduced-dose regimen than in those allocated to the standard-dose regimen. All patients received the same glucocorticoid dosing from 6 to 12 months. Subsequent dosing was at the discretion of the treating physician. Primary outcome The primary outcome was a composite of all-cause mortality and end-stage renal disease at a common close-out when the last patient had completed 10 months in the trial. Results The study recruited 704 patients from June 2010 to September 2016. Ninety-nine patients died and 138 developed end-stage renal disease, with the primary end point occurring in 209 out of 704 (29.7%) patients: 100 out of 352 (28%) in the plasma exchange group and 109 out of 352 (31%) in the no plasma exchange group (adjusted hazard ratio 0.86, 95% confidence interval 0.65 to 1.13; p = 0.3). In the per-protocol analysis for the non-inferiority glucocorticoid comparison, the primary end point occurred in 92 out of 330 (28%) patients in the reduced-dose group and 83 out of 325 (26%) patients in the standard-dose group (partial-adjusted risk difference 0.023, 95% confidence interval 0.034 to 0.08; p = 0.5), thus meeting our non-inferiority hypothesis. Serious infections in the first year occurred in 96 out of 353 (27%) patients in the reduced-dose group and in 116 out of 351 (33%) patients in the standard-dose group. The rate of serious infections at 1 year was lower in the reduced-dose group than in the standard-dose group (incidence rate ratio 0.69, 95% confidence interval 0.52 to 0.93; p = 0.016). Conclusions Plasma exchange did not prolong the time to death and/or end-stage renal disease in patients with anti-neutrophil cytoplasm antibody-associated vasculitis with severe renal or pulmonary involvement. A reduced-dose glucocorticoid regimen was non-inferior to a standard-dose regimen and was associated with fewer serious infections. Future work A meta-analysis examining the effects of plasma exchange on kidney outcomes in anti-neutrophil cytoplasm antibody-associated vasculitis is planned. A health-economic analysis of data collected in this study to examine the impact of both plasma exchange and reduced glucocorticoid dosing is planned to address the utility of plasma exchange for reducing early end-stage renal disease rates. Blood and tissue samples collected in the study will be examined to identify predictors of response to plasma exchange in anti-neutrophil cytoplasm in antibody-associated vasculitis. The benefits associated with reduced glucocorticoid dosing will inform future studies of newer therapies to permit further reduction in glucocorticoid exposure. Data from this study will contribute to updated management recommendations for anti-neutrophil cytoplasm antibody-associated vasculitis. Limitations This study had an open-label design which may have permitted observer bias; however, the nature of the end points, end-stage renal disease and death, would have minimised this risk. Despite being, to our knowledge, the largest ever trial in anti-neutrophil cytoplasm antibody-associated vasculitis, there was an insufficient sample size to assess clinically useful benefits on the separate components of the primary end-point: end-stage renal disease and death. Use of a fixed-dose plasma exchange regimen determined by consensus rather than data-driven dose ranging meant that some patients may have been underdosed, thus reducing the therapeutic impact. In particular, no biomarkers have been identified to help determine dosing in a particular patient, although this is one of the goals of the biomarker plan of this study. Trial registration This trial is registered as ISRCTN07757494, EudraCT 2009-013220-24 and Clinicaltrials.gov NCT00987389. Funding This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 26, No. 38. See the NIHR Journals Library website for further project information.